Clinical and preclinical studies have confirmed that FMD results in reduced glucose levels within tumor tissues [6, 20], suggesting its potential to inhibit the pro-tumor functions of hypoxic TAMs and synergize with AAT. This evidence concerns the gene SERPINA1 and neoplasm.